P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Lindsey E. Roeker,Haesook T. Kim,Brett Glotzbecker,Prashant Nageshwar,Sarah Nikiforow,John Koreth,Philippe Armand,Corey Cutler,Edwin P. Alyea,Joseph H. Antin,Paul G. Richardson,Robert J. Soiffer,Vincent T. Ho +12 more
TL;DR: Acute renal dysfunction, platelet refractoriness, and elevated or abnormal tacrolimus levels are dynamic clinical markers that should alert clinicians to the development of VOD/SOS before the presence of classical diagnostic criteria.
Journal ArticleDOI
Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes.
Sara Fernández,Ana Belen Moreno-Castaño,Marta Palomo,Julia Martinez-Sanchez,Sergi Torramade-Moix,Adrián Téllez,Helena Ventosa,Ferran Segui,Gines Escolar,Enric Carreras,Josep M. Nicolás,Edward Richardson,David García-Bernal,Carmelo Carlo-Stella,José M. Moraleda,Paul G. Richardson,Maribel Diaz-Ricart,Pedro Castro +17 more
TL;DR: In this paper, the level of each biomarker in all three COVID-19 groups and healthy donors as controls were compared with other intensive care unit (ICU) patients with septic shock (SS), sepsis (S, nâ´=â7), and noninfectious systemic inflammatory response syndrome (NI-SIRS, N, S, and NI SIRS).
Journal ArticleDOI
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
Peter M. Voorhees,Cesar Rodriguez,Brandi Reeves,Nitya Nathwani,Luciano J. Costa,Yana Lutska,Daniela Hoehn,Huiling Pei,Jon Ukropec,Ming Qi,Thomas S. Lin,Paul G. Richardson +11 more
TL;DR: In this paper, Dara, a human IgGκ monoclonal antibody that targets CD38, is approved as monotherapy and in combination with Vd, Rd, and pomalidomide-d for the treatment of relapsed MM.
Journal ArticleDOI
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Laurence Catley,Yu-Tzu Tai,Reshma Shringarpure,Renate Burger,Moni Thi Son,Klaus Podar,Pierfrancesco Tassone,Dharminder Chauhan,Teru Hideshima,Louis Denis,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +12 more
TL;DR: It is shown for the first time that SN38, the potent active metabolite of irinotecan, induces c-Jun NH2-terminal kinase activation, Fas up-regulation, and caspase 8-mediated apoptosis in multiple myeloma (MM) cells.
Journal ArticleDOI
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies
Richard Rickles,Laura T. Pierce,Thomas Giordano,Winnie F. Tam,Douglas W. McMillin,Jake Delmore,Jacob P. Laubach,Alexis Borisy,Paul G. Richardson,Margaret S. Lee +9 more
TL;DR: An unexpected synergistic interaction between adenosine receptor agonists and phosphodiesterase (PDE) inhibitors that displays substantial activity in a panel of MM and diffuse large B-cell lymphoma (DLBCL) cell lines and tumor cells from MM patients is discovered.